Top Five Global Cardiovascular Drug Companies 2013 Report Features Players such as Pfizer and AstraZeneca

DUBLIN, July 9, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/b9t3dr/top_five_global) has announced the addition of the "Top Five Global Cardiovascular Drug Companies: Performance, Strategies and Competitive Analysis" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The global cardiovascular drugs industry experienced average growth over the last five years and is expected to reach approximately US $174.8 billion in 2017, growing with a CAGR of 2.9% over the next five years. Top companies are making strategic acquisitions both to expand their global footprints and to take advantage of established business and expertise gained from acquired companies.

The report provides detailed insights into the performance of the top five companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.

The global cardiovascular drugs industry is consolidated with all classes of drugs used for the treatment of cardiovascular diseases such as hypertension, high cholesterol, heart failure, acute stroke, abnormal rhythms of the heart, chest pain, and other cardiac disorders. The industry is dominated by the North America region. In this study, Lucintel thoroughly profiles the following five companies with detailed competitive assessments:

- AstraZeneca
- Bristol-Myers Squibb
- Novartis
- Pfizer
- Sanofi

As indicted in the study, the thrombotic drugs segment is currently small, but holds great growth potential in the future. The launch and development of new products, incorporated with innovative technologies, will drive the growth as manufacturers look for ways to differentiate themselves from their competitors.

This study is intended to provide industry leaders with a competitive benchmarking of the world's top five cardiovascular drugs companies. The study provides up-to-date information on the market share, profit margins, capabilities, and strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis and insight, critical to the development and implementation of an effective marketing and sales plan.


For more information visit http://www.researchandmarkets.com/research/b9t3dr/top_five_global  

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare